2609.HK
Biokin does biopharma

Cancer hospital operator Bayzed Health Group Inc. (2609.HK) launched its Hong Kong IPO on Friday, aiming to raise up to HK$900 million ($115 million). The company said it plans to sell 133 million shares at between HK$4.22 and HK$6.75 per share, according to its announcement marking the listing’s launch.

Final pricing will take place on June 19, with trading set to begin on June 23.

Bayzed operates six self-owned hospitals around China engaged in the detection and treatment of cancer. The company reported 1.19 billion yuan ($166 million) in revenue last year, up 11% from 1.07 billion yuan in 2023. Its loss for 2024 narrowed to 13.5 million yuan from a 24.6 million yuan loss the previous year.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Zepp makes wearable products

Zepp hits its stride with return to revenue growth

The maker of low-end wearable devices reported its revenue rose 78.5% in the third quarter, but forecast the rate would ease to about 40% in the current quarter Key Takeaways:…
Man Wah subsidiary Remacro NEEQ listing

Man Wah sets spin-off in motion for its sofa tech unit

The Chinese furniture giant is preparing to list its components subsidiary Remacro to raise the technology unit’s profile and open an independent funding channel Key Takeaways: After listing on China’s…